Effexor "approvable"
Executive Summary
Wyeth receives "approvable" letter for Effexor (venlafaxine) for new indication of prevention of depression relapse and remission. "FDA has accepted the basic data [and] it's now a question of discussion of the final labeling," AHP VP-Investor Relations Justin Victoria says. "Those discussions are underway." The sNDA was filed in May 2000. Effexor, indicated for depression, anxiety and narcotic overdose, generated $208 mil. in U.S. sales in the first quarter, up 14.4%